Verastem Oncology (VSTM) Misses Q3 EPS by 54c

Verastem Oncology (NASDAQ: VSTM) reported Q3 EPS of ($0.54). Revenue for the quarter came in at $11.24 million.

For earnings history and earnings-related data on Verastem Oncology (VSTM) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Select Medical stockholders approve buyout by insider-led consortium
• Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal